Migraine – Pipeline Review, H1 2012

2012-03-06
Published : Mar-2012

Summary

Global Markets Direct’s, ‘Migraine – Pipeline Review, H1 2012’, provides an overview of the Migraine therapeutic pipeline. This report provides information on the therapeutic development for Migraine, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Migraine. ‘Migraine – Pipeline Review, H1 2012’ is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– A snapshot of the global therapeutic scenario for Migraine.
– A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Migraine pipeline on the basis of route of administration and molecule type.
– Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.

Reasons to buy

– Identify and understand important and diverse types of therapeutics under development for Migraine.
– Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
– Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
– Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Migraine therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Migraine Pipeline Trial

Published: February 2012
No. of Pages: 145
Price:US$500     


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Migraine Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Migraine 9
Migraine Therapeutics under Development by Companies 11
Migraine Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Migraine Therapeutics – Products under Development by Companies 22
Migraine Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Migraine Therapeutics Development 24
Sanofi-Aventis 24
Vyteris, Inc. 25
Eli Lilly and Company 26
Vectura Group plc 27
Biofrontera AG 28
Novartis AG 29
Axcan Pharma Inc. 30
Eisai Co., Ltd. 31
Pfizer Inc. 32
Teva Pharmaceutical Industries Limited 33
NuPathe Inc. 34
Capnia, Inc. 35
IntelGenx Technologies Corp. 36
NovaDel Pharma, Inc. 37
Paladin Labs Inc. 38
MAP Pharmaceuticals, Inc. 39
POZEN Inc. 40
Asterand plc. 41
Genizon BioSciences, Inc. 42
D-Pharm Ltd. 43
Physica Pharma 44
MIKA Pharma GmbH 45
Ache Laboratorios Farmaceuticos S/A 46
CoLucid Pharmaceuticals, Inc. 47
Pantarhei Bioscience BV 48
NeurAxon, Inc. 49
Winston Pharmaceuticals, Inc. 50
The EMMES Corporation 51
Trigemina, Inc. 52
Migraine – Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
E2007 – Drug Profile 59
Levadex – Drug Profile 61
EUR 1000 – Drug Profile 63
BF-1 – Drug Profile 64
MK49 – Drug Profile 65
Sumatriptan SDI – Drug Profile 66
PHY 303 – Drug Profile 67
Estetrol – Drug Profile 68
INT0008 – Drug Profile 70
Zolmitriptan – Drug Profile 71
MT 400 – Drug Profile 72
NXN-188 – Drug Profile 74
NXN-462 – Drug Profile 75
nNOS/NET – Drug Profile 76
VR147 – Drug Profile 77
Nasal Carbon Dioxide – Drug Profile 78
NVD-201 – Drug Profile 79
DP-VPA – Drug Profile 80
Candesartan Cilexitil – Drug Profile 82
BGG492 – Drug Profile 83
TI-001 – Drug Profile 85
PF-04427429 – Drug Profile 86
LY2951742 – Drug Profile 87
Metoclopramide – Drug Profile 88
Topiramate – Drug Profile 89
Sodium Valporate – Drug Profile 90
Zelrix – Drug Profile 91
Enalapril – Drug Profile 93
COL-144 – Drug Profile 94
Topiramate + Propranolol – Drug Profile 95
N-Alpha Methyl Histamine – Drug Profile 97
Compazine – Drug Profile 98
Ethosuximide – Drug Profile 99
Metoclopramide + Ketoprofen – Drug Profile 100
BGC20-1531 – Drug Profile 101
Caffeine + Propranolol – Drug Profile 102
Longevity Program – Drug Profile 103
DR-105 – Drug Profile 104
Ketoprofen – Drug Profile 105
Cyclobenzaprine Hydrochloride Extended Release – Drug Profile 106
Dolorac – Drug Profile 107
LY2300559 – Drug Profile 108
Propofol – Drug Profile 109
Dexamethasone – Drug Profile 110
DIS-COM-TRO – Drug Profile 111
RHB-103 – Drug Profile 112
R101 – Drug Profile 113
Simvastatin + Vitamin D – Drug Profile 114
Naratriptan + Naproxen – Drug Profile 115
Topiramate – Drug Profile 116
Topiramate – Drug Profile 117
Ibuprofen + Caffeine – Drug Profile 118
Migraine Therapeutics – Drug Profile Updates 119
Migraine Therapeutics – Discontinued Products 129
Migraine Therapeutics – Dormant Products 130
Migraine – Product Development Milestones 131
Featured News & Press Releases 131
Appendix 140
Methodology 140
Coverage 140
Secondary Research 140
Primary Research 140
Expert Panel Validation 141
Contact Us 141
Disclaimer 141

List of Tables
Number of Products Under Development for Migraine, H1 2012 13
Products under Development for Migraine – Comparative Analysis, H1 2012 14
Number of Products under Development by Companies, H1 2012 16
Number of Products under Development by Companies, H1 2012 (Contd..1) 17
Number of Products under Development by Companies, H1 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2012 20
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 21
Comparative Analysis by Late Stage Development, H1 2012 22
Comparative Analysis by Mid Clinical Stage Development, H1 2012 23
Comparative Analysis by Early Clinical Stage Development, H1 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 25
Products under Development by Companies, H1 2012 26
Products under Investigation by Universities/Institutes, H1 2012 27
Sanofi-Aventis, H1 2012 28
Vyteris, Inc., H1 2012 29
Eli Lilly and Company, H1 2012 30
Vectura Group plc, H1 2012 31
Biofrontera AG, H1 2012 32
Novartis AG, H1 2012 33
Axcan Pharma Inc., H1 2012 34
Eisai Co., Ltd., H1 2012 35
Pfizer Inc., H1 2012 36
Teva Pharmaceutical Industries Limited, H1 2012 37
NuPathe Inc., H1 2012 38
Capnia, Inc., H1 2012 39
IntelGenx Technologies Corp., H1 2012 40
NovaDel Pharma, Inc., H1 2012 41
Paladin Labs Inc., H1 2012 42
MAP Pharmaceuticals, Inc., H1 2012 43
POZEN Inc., H1 2012 44
Asterand plc., H1 2012 45
Genizon BioSciences, Inc., H1 2012 46
D-Pharm Ltd., H1 2012 47
Physica Pharma, H1 2012 48
MIKA Pharma GmbH, H1 2012 49
Ache Laboratorios Farmaceuticos S/A, H1 2012 50
CoLucid Pharmaceuticals, Inc., H1 2012 51
Pantarhei Bioscience BV, H1 2012 52
NeurAxon, Inc., H1 2012 53
Winston Pharmaceuticals, Inc., H1 2012 54
The EMMES Corporation, H1 2012 55
Trigemina, Inc., H1 2012 56
Assessment by Monotherapy Products, H1 2012 57
Assessment by Combination Products, H1 2012 58
Assessment by Stage and Route of Administration, H1 2012 60
Assessment by Stage and Molecule Type, H1 2012 62
Migraine Therapeutics – Drug Profile Updates 123
Migraine Therapeutics – Discontinued Products 133
Migraine Therapeutics – Dormant Products 134

List of Figures
Number of Products under Development for Migraine, H1 2012 13
Products under Development for Migraine – Comparative Analysis, H1 2012 14
Products under Development by Companies, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 19
Late Stage Products, H1 2012 22
Mid Clinical Stage Products, H1 2012 23
Early Clinical Stage Products, H1 2012 24
Discovery and Pre-Clinical Stage Products, H1 2012 25
Assessment by Monotherapy Products, H1 2012 57
Assessment by Combination Products, H1 2012 58
Assessment by Route of Administration, H1 2012 59
Assessment by Stage and Route of Administration, H1 2012 60
Assessment by Molecule Type, H1 2012 61
Assessment by Stage and Molecule Type, H1 2012 62

Filed in: Medical Device, Pharmaceuticals and Healthcare
Tags: 
More Reports
Title Price Buy Now

Wound Care Market by Product (Dressings (Foam, Film, Hydrocolloid, Collagen), Devices (NPWT, Assessment, Debridement), Graft, Matrix, Suture, Stapler), Wound(DFUs, Trauma, Surgical, Burn), End User (Hospitals, Clinics) & Region – Global Forecast to 2027

“Increased cases of traumatic injuries and increasing surgical procedures worldwide are driving the overall growth of the wound care market” The global wound care market is projected to reach USD 27.2 billion by 2027 from USD 20.8 billion in 2022, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as increase in traumatic injuries, increased in number of surgical wounds and increased spending on traumatic wound management. On the other hand, challenges associated with wound care product validation and shortage of skilled professionals are the major factors hampering the growth of this market. “The advanced wound care products segment accounted for the highest growth rate in the wound care market, by product, during the forecast period” T......
 $8150

Rehabilitation Equipment Market by Product (Medical Bed, Mobility Scooter, Walker, Crutcher, Cane, Patient Lift, Sling), Application (Physical, OT, Lower-body Exercise Equipment), End User (Rehabilitation & Physiotherapy Center) – Global Forecast to 2027

“The rehabilitation equipment market is projected to grow at a CAGR of 5.9% between 2022 and 2027.” The global rehabilitation equipment market is projected to reach USD 19.8 billion by 2027 from USD 14.9 billion in 2022, at a CAGR of 5.9% during the forecast period. Increasing geriatric population and obese populations, increasing chronic diseases, high risk of injuries to caregivers during the manual handling of patients, and increasing demand for rehabilitation care, owing to an increasing access to healthcare are the key driving factors in the market. However, a lack of awareness and access to rehabilitation services in emerging countries is a major factor restraining market growth. “Therapy equipment was the largest and fastest-growing segment in the product segment of reha......
 $4950

Cold Pain Therapy Market by Product (OTC (Gels, Creams, Patches, Wraps, Pads), Prescription (Motorized, Non-motorized)), Application (Musculoskeletal, Post-Op, Sports Injuries), Distribution Channel (Hospital, Retail, E-Pharmacy) – Global Forecast to 2027

"Increasing sports injuries and active participation are driving the overall growth of the cold pain therapy market." The global cold pain therapy market is projected to reach USD 2.4 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 5.1% during the forecast period. Growth in this market is mainly driven by growing incidence of arthritis and availability of cold pain products at affordable cost. "The OTC products segment accounted for the highest growth rate in the cold pain therapy market, by product, during the forecast period." The cold pain therapy market is segmented into OTC products and prescription products based on product. In 2021, the OTC products segment accounted for the highest growth rate in the cold pain therapy market. Market growth can largely be attri......
 $4950

Nerve Repair & Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) – Global Forecast to 2027

“Increasing research investments into the neurological compilations and the expanding geriatric population are pushing the growth of the nerve repair & regeneration market.” The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%.The growth in this market is driven by increasing research expenditure on the neurological disorders by the government, the increasing R&D investments by the market players into the neuromodulation and neurostimulation devices and the biomaterials. Also, the expanding geriatric population base dries the growth of the market by placing more demand of the nerve repair and regeneration products. “The biomaterialas segment is anticipated to grow at the fastest ......
 $4950

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) – Global Forecast to 2027

MarketsandMarkets expects particle therapy market is projected to reach USD 1,004 million by 2027 from USD 677 million in 2022, growing at a CAGR of 8.2% from 2022 to 2027. Market growth is driven by factors such as the various advantages offered by the growing global prevalence of cancer, particle therapy advantages over photon therapy, increasing acceptance of particle therapy in clinical trials, and the increasing number of particle therapy centers worldwide. However, affordability & accessibility of treatments and infrastructural are expected to limit market growth to a certain extent in the coming years. In this report, the particle therapy market is segmented on the basis of type, product and services, cancer type, application, cancer type, and region. “Treatment Applicat......
 $4950

Restorative Dentistry Market by Product (Restorative Material (Glass-ionomers, Bonding Agents, Biomaterial), Implant, Prosthetic, Equipment (Handpiece, Articulator, Furnace), End User (Hospital, Clinic, Laboratory) – Global Forecast to 2027

“The global restorative dentistry market is projected to grow at a CAGR of 6.1%” Restorative dentistry restores mouth functions & its aesthetic state by efficiently managing oral health problems through dental restoration. Dental restoration procedures include the use of implants and prosthetics made by restorative material to restore the function, integrity, and morphology of the missing tooth or to repair the missing parts of the tooth structure resulted from dental caries or injuries. The global restorative dentistry market is projected to reach USD 22.2 billion by 2027 from USD 16.5 billion in 2022, at a CAGR of 6.1%. “The prosthetic materials segment is expected to account for the largest share of the restorative dentistry market” The prosthetic materials segment ......
 $4950

Dental Laboratories Market by Material (Metal Ceramic, CAD/CAM Material (Zirconia, Glass Ceramic)), Equipment (Milling Equipment, CAD/CAM System, 3D Printing System, Scanner, Furnace), Prosthetics (Bridge, Crown, Veeners, Denture) – Global Forecast to 2027

“Rapid growth in the geriatric population and the associated increase in the prevalence of edentulism is expected to drive the overall growth of the dental laboratories market.” Edentulism (tooth loss) is a major oral health concern among the elderly; according to the WHO (2020), globally, ~19% of individuals aged between 65 and 74 years are edentulous. Periodontal diseases and dental cavities are the major causes of tooth loss. As the elderly are more susceptible to such ailments, the growth of this population segment will increase the number of people suffering from oral health problems globally. According to the UN, the global geriatric population (aged 65 years and above) will increase from 703 million in 2019 to 1.5 billion in 2050. Thus, significant growth in the geriatric pop......
 $4950

Endoscope Reprocessing Market by Product (HLD and Test Strips, Detergents & Wipes, Automated Endoscope Reprocessors (AER), Endoscope Drying, Storage, & Transport Systems, Tracking Solutions), End User (Hospitals, ASCs & Clinics) (2022 – 2027)

“Endoscope reprocessing market is projected to grow at CAGR of 9.7% from 2022 to 2027” The global endoscope reprocessing market is projected to USD 3.8 billion by 2027 from USD 2.4 billion in 2022, at a CAGR of 9.7% from 2022 to 2027.The growth of this market is driven owing to increasing requirement for endoscopy to diagnose and treat target diseases, high risk of Endoscope-associated infections due to contaminated endoscopes, Growing geriatric population and leading to increase in endoscopic procedures, and Increasing emphasis on improving reprocessing guidelines by healthcare authorities. Also, Increasing investments, funds, and grants to improve healthcare infrastructure and research areas of endoscopy is anticipated to offer an opportunity for the growth of the market during th......
 $4950

Polymethyl Methacrylate (PMMA) Market by Grade (General Purpose, Optical), Form(Extruded Sheet, Cast Acrylic Sheet, Pellets, Beads),End-Use Industry(Signs & Displays, Construction, Automotive, Lighting Fixtures, Electronics, Marine, Healthcare) & Region – Global Forecast to 2027

“Rising demand from the electronics industry and expected recovery from impact of COVID-19 and rising penetration of EVs expected to drive market.” The global Polymethyl Methacrylate (PMMA) market is projected to grow from USD 4.8 Billion in 2022 to USD 6.3 Billion by 2027, at a CAGR of 5.4% during the forecast period. Increasing usage of PMMA in construction, automotive, electronics, and other end-use industries are driving the demand for PMMA during the forecast period. However, availability of low-cost substitutes is expected to hamper market growth. PMMA is a versatile, recyclable, sustainable, and durable material, owing to which it is gaining traction across several industrial applications. Due to its superior properties and the changing government policies such as European Gr......
 $4950

Microtome Market by Product (Instruments, (Rotary), Accessories (Microtome Blades), Application (Disease Diagnosis, Medical Research), Technology (Fully Automated, Semi-automated, Manual), End User (Hospital, Clinical Labs) – Global Forecast to 2027

“The hospital laboratories is projected to grow at CAGR of 7.1% from 2022 to 2027” Based on End user the market is classified into, The hospital laboratories, clinical laboratories, and other end users . The growth of this market is majorly driven by the increasing number of specialty diagnostic tests performed in hospital laboratories, rising number of in-house clinical diagnostic procedures in hospitals, rising number of hospitals across the globe, and the growing trend of establishing in-house clinical diagnostic capabilities in hospitals. “Microtome instruments in the product segment to witness the highest shares during the forecast period.” Based on the product, the microtome market is segmented into Microtome Instruments: Rotary Microtomes, Cryostat Microtomes, Vibra......
 $4950
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy